GILD Gilead Sciences Inc

Price (delayed)

$67.72

Market cap

$84.37B

P/E Ratio

169.3

Dividend/share

$3.02

EPS

$0.4

Enterprise value

$104.85B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's P/E is 189% above its last 4 quarters average of 58.6 and 136% above its 5-year quarterly average of 71.7
The company's net income has shrunk by 91% QoQ and by 91% YoY

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$84.37B
Enterprise value
$104.85B
Valuations
Price to book (P/B)
4.81
Price to sales (P/S)
3.08
EV/EBIT
50.67
EV/EBITDA
21.79
EV/Sales
3.82
Earnings
Revenue
$27.45B
EBIT
$2.07B
EBITDA
$4.81B
Free cash flow
$7.9B
Per share
EPS
$0.4
Free cash flow per share
$6.34
Book value per share
$14.08
Revenue per share
$22.01
TBVPS
$19.69
Balance sheet
Total assets
$56.29B
Total liabilities
$38.84B
Debt
$25.19B
Equity
$17.54B
Working capital
$1.03B
Liquidity
Debt to equity
1.44
Current ratio
1.08
Quick ratio
0.72
Net debt/EBITDA
4.26
Margins
EBITDA margin
17.5%
Gross margin
75.8%
Net margin
1.8%
Operating margin
5.7%
Efficiency
Return on assets
0.8%
Return on equity
2.3%
Return on invested capital
6.2%
Return on capital employed
4.8%
Return on sales
7.5%
Dividend
Dividend yield
4.46%
DPS
$3.02
Payout ratio
755%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
-0.21%
1 week
2.67%
1 month
1.18%
1 year
-14.07%
YTD
-16.41%
QTD
-7.55%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.45B
Gross profit
$20.8B
Operating income
$1.58B
Net income
$484M
Gross margin
75.8%
Net margin
1.8%
Gilead Sciences's net margin has shrunk by 91% QoQ and by 91% YoY
The company's net income has shrunk by 91% QoQ and by 91% YoY
The operating margin has plunged by 83% YoY and by 80% from the previous quarter
The operating income has dropped by 82% year-on-year and by 79% since the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
169.3
P/B
4.81
P/S
3.08
EV/EBIT
50.67
EV/EBITDA
21.79
EV/Sales
3.82
GILD's P/E is 189% above its last 4 quarters average of 58.6 and 136% above its 5-year quarterly average of 71.7
GILD's EPS has dropped by 91% since the previous quarter and by 91% year-on-year
Gilead Sciences's equity has decreased by 23% from the previous quarter and by 16% YoY
The stock's price to book (P/B) is 12% more than its 5-year quarterly average of 4.3 and 4.6% more than its last 4 quarters average of 4.6
GILD's price to sales (P/S) is 12% less than its 5-year quarterly average of 3.5 and 12% less than its last 4 quarters average of 3.5

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 91% since the previous quarter and by 91% year-on-year
The company's return on equity has shrunk by 91% YoY and by 91% QoQ
GILD's return on sales has dropped by 75% year-on-year and by 74% since the previous quarter
Gilead Sciences's ROIC has plunged by 73% YoY and by 73% from the previous quarter

Dividends

What is GILD's dividend history
DPS
$3.02
Dividend yield
4.46%
Payout ratio
755%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 45% higher than its total liabilities
The quick ratio has contracted by 32% from the previous quarter and by 24% YoY
Gilead Sciences's current ratio has decreased by 24% QoQ and by 16% YoY
Gilead Sciences's debt is 44% higher than its equity
The company's debt to equity rose by 32% QoQ and by 20% YoY
Gilead Sciences's equity has decreased by 23% from the previous quarter and by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.